ClearPoint Neuro (CLPT) Financials

$12.40 -0.39 (-3.05%)

As of 11:22 AM Eastern

Annual Income Statements for ClearPoint Neuro

This table shows ClearPoint Neuro's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-19	-22	-16
Consolidated Net Income / (Loss)	-19	-22	-16
Net Income / (Loss) Continuing Operations	-19	-22	-16
Total Pre-Tax Income	-19	-22	-16
Total Operating Income	-20	-22	-16
Total Gross Profit	19	14	14
Total Revenue	31	24	21
Operating Revenue	31	24	21
Total Cost of Revenue	12	10	7.02
Operating Cost of Revenue	12	10	7.02
Total Operating Expenses	39	36	30
Selling, General & Admin Expense	12	12	9.61
Marketing Expense	14	13	9.36
Research & Development Expense	12	12	11
Total Other Income / (Expense), net	0.83	0.39	-0.10
Interest Expense	-0.87	-0.39	0.08
Other Income / (Expense), net	-0.04	-	-0.02
Basic Earnings per Share	($0.70)	($0.90)	($0.68)
Weighted Average Basic Shares Outstanding	27.03M	24.61M	24.18M
Diluted Earnings per Share	($0.70)	($0.90)	($0.68)
Weighted Average Diluted Shares Outstanding	27.03M	24.61M	24.18M
Weighted Average Basic & Diluted Shares Outstanding	27.63M	26.98M	24.61M

This table shows ClearPoint Neuro's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-5.39	-4.97	-4.41	-4.15	-4.62	-4.81	-7.05	-5.61	-4.39	-3.79
Consolidated Net Income / (Loss)	-5.39	-4.97	-4.41	-4.15	-4.62	-4.81	-7.05	-5.61	-4.39	-3.79
Net Income / (Loss) Continuing Operations	-5.39	-4.97	-4.41	-4.15	-4.62	-4.81	-7.05	-5.61	-4.39	-3.79
Total Pre-Tax Income	-5.39	-4.97	-4.41	-4.15	-4.60	-4.80	-7.05	-5.61	-4.39	-3.79
Total Operating Income	-5.60	-5.17	-4.74	-4.23	-4.71	-4.90	-7.13	-5.71	-4.47	-3.80
Total Gross Profit	4.76	4.85	4.99	4.53	4.01	3.27	3.13	3.20	3.37	3.68
Total Revenue	7.77	8.12	7.86	7.64	6.81	5.76	5.95	5.43	5.17	5.15
Operating Revenue	7.77	8.12	7.86	7.64	6.81	5.76	5.95	5.43	5.17	5.15
Total Cost of Revenue	3.01	3.28	2.87	3.11	2.80	2.49	2.82	2.23	1.81	1.47
Operating Cost of Revenue	3.01	3.28	2.87	3.11	2.80	2.49	2.82	2.23	1.81	1.47
Total Operating Expenses	10	10	9.73	8.76	8.72	8.17	10	8.91	7.84	7.47
Selling, General & Admin Expense	3.23	3.16	2.77	2.84	2.72	2.90	3.18	2.96	2.38	2.40
Marketing Expense	3.81	3.55	3.83	3.29	3.35	2.84	3.47	2.93	2.53	2.42
Research & Development Expense	3.33	3.32	3.12	2.63	2.65	2.43	3.61	3.02	2.93	2.65
Total Other Income / (Expense), net	0.22	0.20	0.33	0.09	0.10	0.10	0.08	0.10	0.08	0.01
Interest Expense	-0.23	-0.21	-0.33	-0.11	-0.09	-0.10	-0.08	-0.11	-0.08	-0.03
Other Income / (Expense), net	-0.01	-0.01	0.01	-0.03	-	-	-0.00	-0.01	-	-0.03
Basic Earnings per Share	($0.20)	($0.18)	($0.16)	($0.16)	($0.18)	($0.20)	($0.29)	($0.23)	($0.18)	($0.15)
Weighted Average Basic Shares Outstanding	27.03M	27.59M	27.47M	25.45M	24.61M	24.63M	24.58M	24.58M	24.18M	24.50M
Diluted Earnings per Share	($0.20)	($0.18)	($0.16)	($0.16)	($0.18)	($0.20)	($0.29)	($0.23)	($0.18)	($0.15)
Weighted Average Diluted Shares Outstanding	27.03M	27.59M	27.47M	25.45M	24.61M	24.63M	24.58M	24.58M	24.18M	24.50M
Weighted Average Basic & Diluted Shares Outstanding	27.63M	27.58M	27.60M	27.42M	26.98M	24.62M	24.64M	24.58M	24.61M	24.55M

This table details how cash moves in and out of ClearPoint Neuro's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-3.04	-4.48	-26
Net Cash From Operating Activities	-8.95	-14	-16
Net Cash From Continuing Operating Activities	-8.95	-14	-16
Net Income / (Loss) Continuing Operations	-19	-22	-16
Consolidated Net Income / (Loss)	-19	-22	-16
Depreciation Expense	0.98	0.63	0.24
Amortization Expense	0.97	0.76	0.30
Non-Cash Adjustments To Reconcile Net Income	6.61	6.58	3.47
Changes in Operating Assets and Liabilities, net	1.40	0.40	-3.75
Net Cash From Investing Activities	-0.28	8.95	-11
Net Cash From Continuing Investing Activities	-0.28	8.95	-11
Purchase of Property, Plant & Equipment	-0.28	-0.72	-0.25
Acquisitions	0.00	-0.33	-0.89
Sale and/or Maturity of Investments	0.00	10	12
Net Cash From Financing Activities	6.19	0.30	0.41
Net Cash From Continuing Financing Activities	6.19	0.30	0.41
Repayment of Debt	-10	0.00	-
Issuance of Common Equity	17	0.51	0.48
Other Financing Activities, net	-0.40	-0.21	-0.07
Cash Interest Paid	0.48	0.74	0.52
Cash Income Taxes Paid	0.06	0.00	0.00

This table details how cash moves in and out of ClearPoint Neuro's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-1.47	-11	-2.51	12	-1.20	-2.12	4.67	-5.82	8.90	-4.81
Net Cash From Operating Activities	-1.24	-1.20	-2.67	-3.84	-1.17	-1.80	-5.08	-5.68	-3.07	-3.85
Net Cash From Continuing Operating Activities	-1.24	-1.20	-2.67	-3.84	-1.17	-1.80	-5.08	-5.68	-3.07	-3.85
Net Income / (Loss) Continuing Operations	-5.39	-4.97	-4.41	-4.15	-4.62	-4.81	-7.05	-5.61	-4.39	-3.79
Consolidated Net Income / (Loss)	-5.39	-4.97	-4.41	-4.15	-4.62	-4.81	-7.05	-5.61	-4.39	-3.79
Depreciation Expense	0.24	-0.20	0.69	0.24	0.18	0.16	0.16	0.13	0.02	0.04
Amortization Expense	0.23	0.71	-0.22	0.25	0.26	0.28	0.14	0.09	0.02	0.01
Non-Cash Adjustments To Reconcile Net Income	1.91	1.90	1.44	1.36	1.14	2.03	1.93	1.48	0.61	1.09
Changes in Operating Assets and Liabilities, net	1.76	1.35	-0.17	-1.54	1.87	0.54	-0.25	-1.77	0.67	-1.21
Net Cash From Investing Activities	-0.26	-0.01	-	0.00	-0.19	-0.24	9.51	-0.14	12	-0.63
Net Cash From Continuing Investing Activities	-0.26	-0.01	-	0.00	-0.19	-0.24	9.51	-0.14	12	-0.63
Purchase of Property, Plant & Equipment	-0.26	-0.01	-	0.00	-0.02	-0.24	-0.32	-0.14	-0.04	-0.07
Net Cash From Financing Activities	0.04	-10	0.16	16	0.16	-0.09	0.24	-0.01	0.22	-0.33
Net Cash From Continuing Financing Activities	0.04	-10	0.16	16	0.16	-0.09	0.24	-0.01	0.22	-0.33
Issuance of Common Equity	0.12	-	0.29	16	0.19	-	0.31	0.00	0.22	-
Other Financing Activities, net	-0.08	-0.06	-0.13	-0.13	-0.04	-0.09	-0.08	-0.01	0.01	-0.33
Cash Income Taxes Paid	0.06	-	-	0.00	-	-	-	0.00	-	-

This table presents ClearPoint Neuro's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	39	43	55
Total Current Assets	33	36	51
Cash & Equivalents	20	23	28
Short-Term Investments	0.00	0.00	9.87
Accounts Receivable	4.71	3.21	2.67
Inventories, net	6.86	7.91	9.30
Prepaid Expenses	1.68	1.91	1.72
Plant, Property, & Equipment, net	2.01	1.39	0.81
Total Noncurrent Assets	3.82	5.10	3.50
Intangible Assets	0.48	1.04	-
Other Noncurrent Operating Assets	3.34	4.06	3.50
Total Liabilities & Shareholders' Equity	39	43	55
Total Liabilities	14	21	19
Total Current Liabilities	10	7.43	6.79
Accounts Payable	1.34	0.39	0.27
Accrued Expenses	1.45	1.05	2.07
Current Deferred Revenue	2.12	2.61	1.07
Current Employee Benefit Liabilities	4.89	2.95	2.82
Other Current Liabilities	0.56	0.42	0.56
Total Noncurrent Liabilities	3.45	14	12
Long-Term Debt	0.00	9.95	9.89
Noncurrent Deferred Revenue	0.44	0.54	0.39
Other Noncurrent Operating Liabilities	3.01	3.57	1.53
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	25	21	37
Total Preferred & Common Equity	25	21	37
Preferred Stock	0.00	0.00	0.00
Total Common Equity	25	21	37
Common Stock	217	194	187
Retained Earnings	-191	-172	-150

This table presents ClearPoint Neuro's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	40	53	54	44	48	50	58
Total Current Assets	34	47	48	37	41	46	54
Cash & Equivalents	22	33	35	24	26	22	19
Accounts Receivable	3.88	3.48	2.51	2.42	2.80	2.68	3.41
Inventories, net	7.06	8.03	7.96	8.99	9.20	9.81	8.28
Prepaid Expenses	1.82	2.21	1.75	1.56	2.24	1.76	1.66
Plant, Property, & Equipment, net	1.70	1.55	1.35	1.36	1.36	0.95	0.63
Total Noncurrent Assets	4.17	4.47	4.72	5.17	5.57	3.31	3.30
Intangible Assets	0.61	0.76	0.89	0.97	-	-	-
Other Noncurrent Operating Assets	3.56	3.72	3.83	4.20	5.57	3.31	3.30
Total Liabilities & Shareholders' Equity	40	53	54	44	48	50	58
Total Liabilities	11	20	19	20	20	18	18
Total Current Liabilities	7.55	17	15	5.59	6.20	6.05	6.10
Accounts Payable	0.96	0.82	0.84	0.79	1.27	1.35	1.39
Accrued Expenses	1.18	1.30	0.99	0.95	1.37	1.40	1.25
Current Deferred Revenue	1.25	1.08	1.23	1.18	0.72	1.28	0.74
Current Employee Benefit Liabilities	3.64	3.00	1.63	2.29	2.34	1.45	2.19
Other Current Liabilities	0.54	0.52	0.50	0.38	0.49	0.57	0.54
Total Noncurrent Liabilities	3.64	3.75	3.90	14	14	12	12
Long-Term Debt	0.00	0.00	0.00	9.94	9.92	9.91	9.88
Noncurrent Deferred Revenue	0.48	0.45	0.46	0.52	0.25	0.32	0.35
Other Noncurrent Operating Liabilities	3.16	3.30	3.44	3.70	3.86	1.39	1.54
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	29	32	35	24	27	33	40
Total Preferred & Common Equity	29	32	35	24	27	33	40
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	29	32	35	24	27	33	40
Common Stock	215	213	211	192	190	189	186
Retained Earnings	-186	-181	-177	-168	-163	-156	-146

This table displays calculated financial ratios and metrics derived from ClearPoint Neuro's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	31.04%	16.56%	26.09%
EBITDA Growth	15.32%	-33.23%	-25.00%
EBIT Growth	11.85%	-37.25%	-21.71%
NOPAT Growth	12.03%	-37.44%	-22.12%
Net Income Growth	14.37%	-34.40%	-14.05%
EPS Growth	22.22%	-32.35%	1.45%
Operating Cash Flow Growth	34.77%	15.14%	-27.33%
Free Cash Flow Firm Growth	22.76%	11.13%	-57.05%
Invested Capital Growth	-33.79%	-14.09%	105.74%
Revenue Q/Q Growth	3.16%	7.33%	4.54%
EBITDA Q/Q Growth	-5.35%	0.75%	-4.45%
EBIT Q/Q Growth	-4.98%	-1.07%	-3.21%
NOPAT Q/Q Growth	-4.76%	-1.07%	-3.07%
Net Income Q/Q Growth	-4.23%	-1.07%	-1.46%
EPS Q/Q Growth	-2.94%	0.00%	4.23%
Operating Cash Flow Q/Q Growth	-0.83%	12.14%	2.92%
Free Cash Flow Firm Q/Q Growth	-1.74%	9.63%	0.60%
Invested Capital Q/Q Growth	-28.85%	-17.60%	-0.05%
Profitability Metrics	-	-	-
Gross Margin	60.92%	56.83%	65.84%
EBITDA Margin	-56.81%	-87.91%	-76.91%
Operating Margin	-62.91%	-93.70%	-79.47%
EBIT Margin	-63.03%	-93.70%	-79.58%
Profit (Net Income) Margin	-60.25%	-92.21%	-79.97%
Tax Burden Percent	100.00%	100.13%	100.00%
Interest Burden Percent	95.59%	98.28%	100.50%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-208.37%	-181.93%	-165.60%
ROIC Less NNEP Spread (ROIC-NNEP)	-177.78%	-150.66%	-151.68%
Return on Net Nonoperating Assets (RNNOA)	127.13%	105.84%	127.24%
Return on Equity (ROE)	-81.24%	-76.09%	-38.37%
Cash Return on Invested Capital (CROIC)	-167.71%	-166.77%	-234.77%
Operating Return on Assets (OROA)	-48.35%	-45.74%	-27.02%
Return on Assets (ROA)	-46.22%	-45.01%	-27.15%
Return on Common Equity (ROCE)	-81.24%	-76.09%	-38.37%
Return on Equity Simple (ROE_SIMPLE)	-74.50%	-104.33%	-44.56%
Net Operating Profit after Tax (NOPAT)	-14	-16	-11
NOPAT Margin	-44.03%	-65.59%	-55.63%
Net Nonoperating Expense Percent (NNEP)	-30.59%	-31.27%	-13.92%
Return On Investment Capital (ROIC_SIMPLE)	-54.44%	-50.49%	-
Cost of Revenue to Revenue	39.08%	43.17%	34.16%
SG&A Expenses to Revenue	38.22%	49.08%	46.77%
R&D to Revenue	39.48%	48.88%	53.01%
Operating Expenses to Revenue	123.82%	150.53%	145.31%
Earnings before Interest and Taxes (EBIT)	-20	-22	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-18	-21	-16
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	16.71	7.90	5.64
Price to Tangible Book Value (P/TBV)	17.03	8.30	5.64
Price to Revenue (P/Rev)	13.52	6.98	10.12
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	76.47	19.29	19.41
Enterprise Value to Revenue (EV/Rev)	12.88	6.43	8.78
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.47	0.27
Long-Term Debt to Equity	0.00	0.47	0.27
Financial Leverage	-0.72	-0.70	-0.84
Leverage Ratio	1.76	1.69	1.41
Compound Leverage Factor	1.68	1.66	1.42
Debt to Total Capital	0.00%	31.97%	21.15%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	31.97%	21.15%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	68.03%	78.85%
Debt to EBITDA	0.00	-0.47	-0.63
Net Debt to EBITDA	0.00	0.63	1.75
Long-Term Debt to EBITDA	0.00	-0.47	-0.63
Debt to NOPAT	0.00	-0.63	-0.87
Net Debt to NOPAT	0.00	0.84	2.41
Long-Term Debt to NOPAT	0.00	-0.63	-0.87
Altman Z-Score	11.45	-1.36	3.27
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.22	4.87	7.54
Quick Ratio	2.40	3.55	5.92
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-11	-14	-16
Operating Cash Flow to CapEx	-3,254.55%	-1,913.53%	-6,390.12%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-200.09
Operating Cash Flow to Interest Expense	0.00	0.00	-199.59
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-202.72
Efficiency Ratios	-	-	-
Asset Turnover	0.77	0.49	0.34
Accounts Receivable Turnover	7.92	8.15	8.22
Inventory Turnover	1.66	1.20	0.99
Fixed Asset Turnover	18.50	21.83	30.56
Accounts Payable Turnover	14.16	31.10	20.09
Days Sales Outstanding (DSO)	46.07	44.77	44.42
Days Inventory Outstanding (DIO)	219.78	303.80	370.23
Days Payable Outstanding (DPO)	25.78	11.74	18.17
Cash Conversion Cycle (CCC)	240.07	336.83	396.47
Capital & Investment Metrics	-	-	-
Invested Capital	5.29	7.98	9.29
Invested Capital Turnover	4.73	2.77	2.98
Increase / (Decrease) in Invested Capital	-2.70	-1.31	4.78
Enterprise Value (EV)	404	154	180
Market Capitalization	424	167	208
Book Value per Share	$0.92	$0.86	$1.50
Tangible Book Value per Share	$0.90	$0.82	$1.50
Total Capital	25	31	47
Total Debt	0.00	9.95	9.89
Total Long-Term Debt	0.00	9.95	9.89
Net Debt	-20	-13	-28
Capital Expenditures (CapEx)	0.28	0.72	0.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)	2.91	5.60	6.90
Debt-free Net Working Capital (DFNWC)	23	29	44
Net Working Capital (NWC)	23	29	44
Net Nonoperating Expense (NNE)	5.09	6.38	5.00
Net Nonoperating Obligations (NNO)	-20	-13	-28
Total Depreciation and Amortization (D&A)	1.95	1.39	0.55
Debt-free, Cash-free Net Working Capital to Revenue	9.26%	23.39%	33.59%
Debt-free Net Working Capital to Revenue	73.30%	119.98%	216.01%
Net Working Capital to Revenue	73.30%	119.98%	216.01%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.70)	($0.90)	($0.68)
Adjusted Weighted Average Basic Shares Outstanding	27.03M	24.61M	24.18M
Adjusted Diluted Earnings per Share	($0.70)	($0.90)	($0.68)
Adjusted Weighted Average Diluted Shares Outstanding	27.03M	24.61M	24.18M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	27.63M	26.98M	24.61M
Normalized Net Operating Profit after Tax (NOPAT)	-14	-16	-11
Normalized NOPAT Margin	-44.03%	-65.59%	-55.63%
Pre Tax Income Margin	-60.25%	-92.09%	-79.97%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	-201.90
NOPAT to Interest Expense	0.00	0.00	-141.14
EBIT Less CapEx to Interest Expense	0.00	0.00	-205.02
NOPAT Less CapEx to Interest Expense	0.00	0.00	-144.26
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from ClearPoint Neuro's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.11%	40.96%	32.07%	40.60%	31.62%	11.97%	14.42%	7.99%	20.83%	12.51%
EBITDA Growth	-20.48%	-4.62%	37.74%	31.58%	3.61%	-18.24%	-71.87%	-52.09%	-17.12%	-6.58%
EBIT Growth	-19.25%	-5.84%	33.63%	25.62%	-5.30%	-28.19%	-69.67%	-48.53%	-12.12%	-2.08%
NOPAT Growth	-19.08%	-5.62%	33.54%	25.93%	-5.30%	-29.04%	-69.62%	-47.83%	-12.23%	0.24%
Net Income Growth	-16.61%	-3.43%	37.49%	26.08%	-5.34%	-26.95%	-63.89%	-41.68%	-5.69%	4.82%
EPS Growth	-11.11%	10.00%	44.83%	30.43%	0.00%	-33.33%	-61.11%	-35.29%	14.29%	16.67%
Operating Cash Flow Growth	-6.33%	33.24%	47.43%	32.39%	61.86%	53.37%	-1.89%	-33.05%	13.71%	-16.87%
Free Cash Flow Firm Growth	38.25%	64.35%	79.35%	84.09%	74.88%	51.48%	-26.98%	-76.94%	-111.01%	-123.79%
Invested Capital Growth	-33.79%	-23.32%	-14.73%	-14.48%	-14.09%	4.21%	43.97%	81.53%	105.74%	127.73%
Revenue Q/Q Growth	-4.32%	3.36%	2.87%	12.17%	18.19%	-3.16%	9.52%	5.01%	0.54%	-1.04%
EBITDA Q/Q Growth	-10.18%	-9.61%	-12.98%	11.78%	4.33%	34.77%	-24.15%	-24.40%	-17.36%	5.18%
EBIT Q/Q Growth	-8.28%	-9.48%	-11.21%	9.62%	3.90%	31.35%	-24.64%	-28.06%	-16.99%	9.13%
NOPAT Q/Q Growth	-8.35%	-9.14%	-12.01%	10.09%	3.90%	31.33%	-24.84%	-27.81%	-17.76%	9.73%
Net Income Q/Q Growth	-8.28%	-12.84%	-6.32%	10.24%	3.95%	31.81%	-25.73%	-27.91%	-15.76%	11.97%
EPS Q/Q Growth	-11.11%	-12.50%	0.00%	11.11%	10.00%	31.03%	-26.09%	-27.78%	-20.00%	16.67%
Operating Cash Flow Q/Q Growth	-3.67%	55.06%	30.52%	-228.49%	34.91%	64.61%	10.65%	-85.32%	20.43%	22.67%
Free Cash Flow Firm Q/Q Growth	9.96%	20.68%	-22.18%	29.24%	48.02%	54.05%	5.85%	-11.69%	-0.42%	-20.26%
Invested Capital Q/Q Growth	-28.85%	-19.84%	0.77%	15.20%	-17.60%	-10.86%	1.07%	15.72%	-0.05%	23.16%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	61.28%	59.68%	63.48%	59.24%	58.93%	56.80%	52.54%	58.94%	65.06%	71.49%
EBITDA Margin	-66.16%	-57.45%	-54.17%	-49.33%	-62.66%	-77.40%	-114.91%	-101.36%	-85.56%	-73.30%
Operating Margin	-72.11%	-63.68%	-60.31%	-55.39%	-69.10%	-84.99%	-119.85%	-105.14%	-86.37%	-73.75%
EBIT Margin	-72.22%	-63.81%	-60.24%	-55.73%	-69.10%	-84.99%	-119.88%	-105.34%	-86.37%	-74.23%
Profit (Net Income) Margin	-69.31%	-61.24%	-56.10%	-54.27%	-67.83%	-83.46%	-118.52%	-103.24%	-84.75%	-73.61%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.37%	100.25%	100.00%	100.00%	99.82%	100.00%
Interest Burden Percent	95.97%	95.97%	93.11%	97.39%	97.79%	97.96%	98.86%	98.01%	98.30%	99.16%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-238.87%	-158.50%	-117.71%	-101.70%	-134.17%	-139.89%	-197.75%	-184.95%	-179.99%	-151.72%
ROIC Less NNEP Spread (ROIC-NNEP)	-230.08%	-150.98%	-112.18%	-96.68%	-127.68%	-133.75%	-189.79%	-179.72%	-176.49%	-148.51%
Return on Net Nonoperating Assets (RNNOA)	164.53%	102.31%	74.25%	67.97%	89.69%	94.06%	140.03%	141.46%	148.05%	124.86%
Return on Equity (ROE)	-74.35%	-56.19%	-43.47%	-33.73%	-44.48%	-45.83%	-57.72%	-43.50%	-31.94%	-26.86%
Cash Return on Invested Capital (CROIC)	-167.71%	-127.78%	-113.25%	-131.53%	-166.77%	-167.91%	-196.51%	-210.55%	-234.77%	-243.77%
Operating Return on Assets (OROA)	-55.39%	-46.22%	-33.75%	-28.07%	-33.73%	-37.35%	-48.23%	-39.41%	-29.32%	-23.08%
Return on Assets (ROA)	-53.16%	-44.35%	-31.42%	-27.34%	-33.11%	-36.68%	-47.69%	-38.62%	-28.77%	-22.89%
Return on Common Equity (ROCE)	-74.35%	-56.19%	-43.47%	-33.73%	-44.48%	-45.83%	-57.72%	-43.50%	-31.94%	-26.86%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-62.57%	-55.96%	-59.64%	0.00%	-90.71%	-76.01%	-55.51%	0.00%	-40.62%
Net Operating Profit after Tax (NOPAT)	-3.92	-3.62	-3.32	-2.96	-3.29	-3.43	-4.99	-4.00	-3.13	-2.66
NOPAT Margin	-50.48%	-44.58%	-42.22%	-38.77%	-48.37%	-59.49%	-83.89%	-73.59%	-60.46%	-51.62%
Net Nonoperating Expense Percent (NNEP)	-8.79%	-7.52%	-5.54%	-5.02%	-6.50%	-6.14%	-7.95%	-5.23%	-3.50%	-3.20%
Return On Investment Capital (ROIC_SIMPLE)	-15.45%	-	-	-	-10.58%	-	-	-	-	-
Cost of Revenue to Revenue	38.72%	40.32%	36.52%	40.76%	41.07%	43.20%	47.46%	41.06%	34.94%	28.51%
SG&A Expenses to Revenue	41.55%	38.85%	35.29%	37.19%	39.94%	50.33%	53.41%	54.45%	45.92%	46.60%
R&D to Revenue	42.88%	40.82%	39.70%	34.36%	38.94%	42.16%	60.59%	55.64%	56.59%	51.57%
Operating Expenses to Revenue	133.39%	123.36%	123.78%	114.62%	128.03%	141.79%	172.39%	164.07%	151.43%	145.24%
Earnings before Interest and Taxes (EBIT)	-5.61	-5.18	-4.73	-4.26	-4.71	-4.90	-7.13	-5.72	-4.47	-3.82
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.14	-4.67	-4.26	-3.77	-4.27	-4.46	-6.84	-5.51	-4.43	-3.77
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	16.71	10.67	4.60	5.30	7.90	5.12	6.49	6.38	5.64	6.36
Price to Tangible Book Value (P/TBV)	17.03	10.90	4.71	5.44	8.30	5.34	6.49	6.38	5.64	6.36
Price to Revenue (P/Rev)	13.52	10.17	5.27	7.01	6.98	5.53	8.20	9.91	10.12	12.90
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	76.47	38.74	13.48	17.19	19.29	11.25	14.86	17.29	19.41	24.00
Enterprise Value to Revenue (EV/Rev)	12.88	9.46	4.45	6.04	6.43	4.88	7.44	8.87	8.78	11.35
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.31	0.29	0.47	0.41	0.36	0.30	0.27	0.25
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.47	0.41	0.36	0.30	0.27	0.25
Financial Leverage	-0.72	-0.68	-0.66	-0.70	-0.70	-0.70	-0.74	-0.79	-0.84	-0.84
Leverage Ratio	1.76	1.58	1.68	1.55	1.69	1.59	1.54	1.43	1.41	1.51
Compound Leverage Factor	1.69	1.52	1.57	1.51	1.65	1.56	1.52	1.40	1.39	1.49
Debt to Total Capital	0.00%	0.00%	23.70%	22.37%	31.97%	29.20%	26.58%	23.32%	21.15%	19.85%
Short-Term Debt to Total Capital	0.00%	0.00%	23.70%	22.37%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	31.97%	29.20%	26.58%	23.32%	21.15%	19.85%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	76.30%	77.63%	68.03%	70.80%	73.42%	76.68%	78.85%	80.15%
Debt to EBITDA	0.00	0.00	-0.60	-0.52	-0.47	-0.47	-0.48	-0.56	-0.63	-0.65
Net Debt to EBITDA	0.00	0.00	1.36	1.31	0.63	0.68	0.81	1.23	1.75	2.02
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-0.47	-0.47	-0.48	-0.56	-0.63	-0.65
Debt to NOPAT	0.00	0.00	-0.77	-0.68	-0.63	-0.64	-0.67	-0.78	-0.87	-0.89
Net Debt to NOPAT	0.00	0.00	1.76	1.73	0.84	0.93	1.12	1.72	2.41	2.76
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-0.63	-0.64	-0.67	-0.78	-0.87	-0.89
Altman Z-Score	12.64	11.24	0.44	2.12	0.01	-0.60	1.32	3.70	3.98	6.10
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.22	4.54	2.79	3.14	4.87	6.68	6.56	7.60	7.54	8.83
Quick Ratio	2.40	3.37	2.18	2.50	3.55	4.79	4.72	5.68	5.92	7.20
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1.23	-1.36	-1.72	-1.40	-1.99	-3.82	-8.31	-8.83	-7.90	-7.87
Operating Cash Flow to CapEx	-472.62%	-9,991.67%	0.00%	0.00%	-5,566.67%	-764.26%	-1,571.21%	-4,115.94%	-7,858.97%	-5,582.61%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.77	0.72	0.56	0.50	0.49	0.44	0.40	0.37	0.34	0.31
Accounts Receivable Turnover	7.92	9.66	8.95	10.08	8.15	7.65	7.06	8.52	8.22	6.59
Inventory Turnover	1.66	1.50	1.31	1.26	1.20	1.08	1.05	0.96	0.99	1.03
Fixed Asset Turnover	18.50	19.95	19.32	22.79	21.83	22.50	21.18	25.28	30.56	36.44
Accounts Payable Turnover	14.16	13.83	10.76	10.22	31.10	8.60	5.82	6.43	20.09	5.82
Days Sales Outstanding (DSO)	46.07	37.78	40.79	36.20	44.77	47.71	51.69	42.86	44.42	55.42
Days Inventory Outstanding (DIO)	219.78	242.90	279.09	288.90	303.80	337.04	347.10	380.63	370.23	354.19
Days Payable Outstanding (DPO)	25.78	26.40	33.93	35.71	11.74	42.46	62.77	56.75	18.17	62.69
Cash Conversion Cycle (CCC)	240.07	254.28	285.96	289.40	336.83	342.28	336.02	366.74	396.47	346.93
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	5.29	7.43	9.27	9.20	7.98	9.69	11	11	9.29	9.30
Invested Capital Turnover	4.73	3.56	2.79	2.62	2.77	2.35	2.36	2.51	2.98	2.94
Increase / (Decrease) in Invested Capital	-2.70	-2.26	-1.60	-1.56	-1.31	0.39	3.32	4.83	4.78	5.21
Enterprise Value (EV)	404	288	125	158	154	109	161	186	180	223
Market Capitalization	424	309	148	183	167	123	178	208	208	254
Book Value per Share	$0.92	$1.05	$1.17	$1.28	$0.86	$0.98	$1.12	$1.32	$1.50	$1.63
Tangible Book Value per Share	$0.90	$1.03	$1.14	$1.25	$0.82	$0.94	$1.12	$1.32	$1.50	$1.63
Total Capital	25	29	42	45	31	34	37	42	47	50
Total Debt	0.00	0.00	9.98	9.96	9.95	9.94	9.92	9.91	9.89	9.88
Total Long-Term Debt	0.00	0.00	0.00	0.00	9.95	9.94	9.92	9.91	9.89	9.88
Net Debt	-20	-22	-23	-25	-13	-14	-17	-22	-28	-31
Capital Expenditures (CapEx)	0.26	0.01	0.00	0.00	0.02	0.24	0.32	0.14	0.04	0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)	2.91	5.20	7.00	7.02	5.60	7.38	8.05	8.20	6.90	7.26
Debt-free Net Working Capital (DFNWC)	23	27	40	42	29	32	35	40	44	48
Net Working Capital (NWC)	23	27	30	32	29	32	35	40	44	48
Net Nonoperating Expense (NNE)	1.46	1.35	1.09	1.18	1.32	1.38	2.06	1.61	1.26	1.13
Net Nonoperating Obligations (NNO)	-20	-22	-23	-25	-13	-14	-17	-22	-28	-31
Total Depreciation and Amortization (D&A)	0.47	0.52	0.48	0.49	0.44	0.44	0.30	0.22	0.04	0.05
Debt-free, Cash-free Net Working Capital to Revenue	9.26%	17.10%	24.92%	26.85%	23.39%	33.06%	37.07%	39.12%	33.59%	36.92%
Debt-free Net Working Capital to Revenue	73.30%	88.00%	141.94%	161.99%	119.98%	142.13%	159.01%	190.57%	216.01%	242.73%
Net Working Capital to Revenue	73.30%	88.00%	106.39%	123.90%	119.98%	142.13%	159.01%	190.57%	216.01%	242.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.20)	($0.18)	($0.16)	($0.16)	($0.18)	($0.20)	($0.29)	($0.23)	($0.18)	($0.15)
Adjusted Weighted Average Basic Shares Outstanding	27.03M	27.59M	27.47M	25.45M	24.61M	24.63M	24.58M	24.58M	24.18M	24.50M
Adjusted Diluted Earnings per Share	($0.20)	($0.18)	($0.16)	($0.16)	($0.18)	($0.20)	($0.29)	($0.23)	($0.18)	($0.15)
Adjusted Weighted Average Diluted Shares Outstanding	27.03M	27.59M	27.47M	25.45M	24.61M	24.63M	24.58M	24.58M	24.18M	24.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	27.63M	27.58M	27.60M	27.42M	26.98M	24.62M	24.64M	24.58M	24.61M	24.55M
Normalized Net Operating Profit after Tax (NOPAT)	-3.92	-3.62	-3.32	-2.96	-3.29	-3.43	-4.99	-4.00	-3.13	-2.66
Normalized NOPAT Margin	-50.48%	-44.58%	-42.22%	-38.77%	-48.37%	-59.49%	-83.89%	-73.59%	-60.46%	-51.62%
Pre Tax Income Margin	-69.31%	-61.24%	-56.10%	-54.27%	-67.58%	-83.25%	-118.52%	-103.24%	-84.91%	-73.61%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About ClearPoint Neuro's Financials

When does ClearPoint Neuro's fiscal year end?

According to the most recent income statement we have on file, ClearPoint Neuro's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has ClearPoint Neuro's net income changed over the last 2 years?

ClearPoint Neuro's net income appears to be on an upward trend, with a most recent value of -$18.91 million in 2024, rising from -$16.44 million in 2022. The previous period was -$22.09 million in 2023. See ClearPoint Neuro's forecast for analyst expectations on what’s next for the company.

What is ClearPoint Neuro's operating income?

ClearPoint Neuro's total operating income in 2024 was -$19.75 million, based on the following breakdown:

Total Gross Profit: $19.12 million
Total Operating Expenses: $38.87 million

How has ClearPoint Neuro revenue changed over the last 2 years?

Over the last 2 years, ClearPoint Neuro's total revenue changed from $20.55 million in 2022 to $31.39 million in 2024, a change of 52.7%.

How much debt does ClearPoint Neuro have?

ClearPoint Neuro's total liabilities were at $13.80 million at the end of 2024, a 35.8% decrease from 2023, and a 25.8% decrease since 2022.

How much cash does ClearPoint Neuro have?

In the past 2 years, ClearPoint Neuro's cash and equivalents has ranged from $20.10 million in 2024 to $27.62 million in 2022, and is currently $20.10 million as of their latest financial filing in 2024.

How has ClearPoint Neuro's book value per share changed over the last 2 years?

Over the last 2 years, ClearPoint Neuro's book value per share changed from 1.50 in 2022 to 0.92 in 2024, a change of -38.7%.

Related Companies

This page (NASDAQ:CLPT) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ClearPoint Neuro (CLPT) Financials

Frequently Asked Questions About ClearPoint Neuro's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ClearPoint Neuro (CLPT) Financials

Annual Income Statements for ClearPoint Neuro

Quarterly Income Statements for ClearPoint Neuro

Annual Cash Flow Statements for ClearPoint Neuro

Quarterly Cash Flow Statements for ClearPoint Neuro

Annual Balance Sheets for ClearPoint Neuro

Quarterly Balance Sheets for ClearPoint Neuro

Annual Metrics And Ratios for ClearPoint Neuro

Quarterly Metrics And Ratios for ClearPoint Neuro

Frequently Asked Questions About ClearPoint Neuro's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools